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Abstract
Short-acting β2-agonist bronchodilators are the most common medications used in treating chronic 
obstructive pulmonary disease (COPD). Genetic variants determining bronchodilator 
responsiveness (BDR) in COPD have not been identified.
We performed a genome-wide association study (GWAS) of BDR in 5789 current or former 
smokers with COPD in one African American and four white populations. BDR was defined as 
the quantitative spirometric response to inhaled β2-agonists. We combined results in a meta-
analysis.
In the meta-analysis, SNPs in the genes KCNK1 (P=2.02×10−7) and KCNJ2 (P=1.79×10−7) were 
the top associations with BDR. Among African Americans, SNPs in CDH13 were significantly 
associated with BDR (P=5.1×10−9). A nominal association with CDH13 was identified in a gene-
based analysis in all subjects.
We identified suggestive association with BDR among COPD subjects for variants near two 
potassium channel genes (KCNK1 and KCNJ2). SNPs in CDH13 were significantly associated 
with BDR in African Americans.
Introduction
Chronic obstructive pulmonary disease (COPD) is a disorder characterized by progressive 
loss of lung function. It is currently the third leading cause of death world-wide, and the 
global burden of disease is expected to continue to rise(1). Although cigarette smoke is the 
greatest risk factor for COPD, recent studies have identified several genetic risk factors for 
this disease(2).
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Inhaled bronchodilators, including β2-agonists, play a key role in COPD management 
guidelines. These medications act on smooth muscle receptors in bronchial airways to 
produce muscle relaxation and airway dilation, resulting in improved airflow through the 
lungs (1), and have been shown to alleviate COPD symptoms(3). The response to inhaled 
bronchodilators is measured by a change in the forced expiratory volume in one second 
(FEV1) using standardized spirometry before and after the administration of β2-agonists. 
Although COPD is characterized by relatively fixed airflow limitation, up to two-thirds of 
COPD patients will exhibit a positive response to an inhaled bronchodilator at any one 
time(4).
The quantitative response to inhaled β2-agonists is a heritable trait(5), and candidate gene 
studies have identified several genes suggestive of association with quantitative measures of 
bronchodilator responsiveness (BDR)(6, 7). In addition, candidate gene(8) and genome-wide 
association studies (GWAS) have identified variants associated with BDR in subjects with 
asthma (9–11). We hypothesized that genome-wide association studies would identify 
associations with BDR in COPD.
Subjects and Methods
Study subjects
Details of the COPDGene, ECLIPSE, GenKOLS, and NETT studies, including study 
procedures, genotyping, and quality control, have been reported(12–16). COPDGene 
subjects were current and former smoking non-Hispanic white (NHW) or African American 
(AA) from the U.S. ECLIPSE subjects were Caucasian current or former smokers from 
Europe, North American and New Zealand. GenKOLS subjects were current and former 
smokers from Norway. NETT subjects were white former smokers from the U.S. All 
subjects had moderate to severe COPD (GOLD stage 2 or greater(17)). Subjects were 
excluded if they had a recent COPD exacerbation.
Spirometry
All subjects completed a respiratory questionnaire and performed standardized spirometry 
according to American Thoracic Society or European Respiratory Society guidelines. 
COPDGene, NETT, and GenKOLS subjects were tested before and approximately 20 
minutes after administration of 2 puffs (180 μg) of inhaled β2-agonist (albuterol/salbutamol). 
ECLIPSE subjects were tested before and 15 minutes after inhalation of 400 μg β2-agonist 
(albuterol/salbutamol).
BDR was measured using three quantitative metrics that have been previously reported(5). 
BDRABS, the absolute difference in pre- versus post- bronchodilator FEV1; BDRPRED, the 
absolute difference in pre- versus post-bronchodilator FEV1 as a percentage of FEV1 percent 
predicted; and BDRBASE, the absolute difference in pre versus post bronchodilator FEV1 as 
a percentage of baseline FEV1.
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Genotyping
All subjects were genotyped using Illumina platforms (Human Hap550 for ECLIPSE and 
GenKOLS, Quad610 for NETT, and Human OmniExpress for COPDGene) as previously 
described(13, 15). We included all variants and subjects that passed quality control, based on 
cluster plots (genotyped) and imputation quality (R2 ≥ 0.80) for imputed SNPs, Hardy-
Weinberg equilibrium (P-value), and missingness (% threshold). Imputation was performed 
using MaCH and minimac with 1000 Genomes phase I v 3 European reference panels for 
white subjects. Cosmopolitan reference panels were used for COPDGene AA subjects. 
Variants with a minor allele frequency (MAF) < 1% and R2 ≤ 0.80 were excluded from 
analysis. Ancestry-based principal components were generated for each study using 
EIGENSOFT2.0(18). We performed Taqman genotyping (Applied Biosystems, Foster City, 
CA) for the SNPs rs114132812 and rs115067260 among 23 and 38 African American 
COPDGene subjects respectively, who were imputed to be carriers of the minor allele.
Statistical analysis
Baseline subject demographics and outcome variables were analyzed in R (v2.15.1). We 
excluded 20 subjects with BDR variables more than six standard deviations from the mean. 
We performed linear regression analysis for the three BDR variables in PLINK(19) 
including genotyped and imputed SNPs, adjusting for age, gender, pack-years smoking 
history, and ancestry-based principal components. We combined the results from all five 
samples in a fixed-effects meta-analysis using METAL(20). We additionally performed a 
gene-based test of significance among the top 20% of all SNPs using VEGAS (a Versatile 
Gene-based test for Genome-wide Association Studies). This method performs gene-based 
association testing by assigning SNPs within 50kb of a gene in accordance with the hg18 
assembly and then uses simulation to account for linkage disequilibrium. All genes are 
tested for association with the trait of interest(21). Using the top 20% of significantly 
associated SNPs, we used VEGAS software to test 13,675 genes. Based on this number, we 
established a Bonferroni significance threshold of 3.6×10−6. We analyzed the top genes from 
our GWAS as well as the top genes identified through the VEGAS analysis using the 
functional annotation tool, DAVID(22, 23).
We tested the association of seven asthma and three COPD SNPs previously associated with 
BDR in asthma GWAS (9, 11) and COPD candidate gene studies (ADRB2, EPHX1, and 
SERPINE2) (6) with BDR in our meta-analysis results. We additionally tested the 
association of two SNPs from the β2-agonist receptor gene, ADRB2 (Arg16Gly, rs1042713 
and Gln27Glu, rs1042714). We tested our top SNPs for their association with lung function 
(FEV1/FVC and FEV1) in the four COPD populations with the broadest range of lung 
function values: COPDGene NHW and AA, GenKOLs, ECLIPSE. We examined our top 
BDR variants for their association with BDR in two asthma GWAS(9, 11).
Results
The demographic data for each study population are presented in Table 1. These outcomes 
appear to follow a normal distribution (Supplementary Figure 1). All three outcomes are 
significantly correlated in COPDGene NHW, but BDRABS and BDRPRED appear more 
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correlated (R2=0.97), compared to BDRABS and BDRBASE (R2=0.85) or BDRBASE and 
BDRPRED (R2=0.88).
The BDR outcomes were statistically different when comparing the four Caucasian 
populations (P<0.05 for ANOVA for all three BDR outcomes). However, these small 
differences are unlikely to be clinically significant. We additionally compared the NHW and 
AA subjects from COPDGene. The AA subjects demonstrated significantly lower 
bronchodilator responsiveness for all three outcomes, and these results remained significant, 
albeit small, after adjusting for age, gender, and pack-years (BDRABS: 0.10 L vs 0.07 L, P 
= 0.004; BDRPRED: 3.59% v 2.80%, P=0.02; BDRBASE: 9.24% vs 7.60%, P=0.007).
Table 2 presents the most significant SNPs from the GWAS in the non-Hispanic white 
subjects from COPDGene. The top SNP annotated to a gene is presented in this table. The 
full list of SNPs with P < 1×10−6 are presented in Supplementary Tables 1–3. SNP 
rs17575208, located upstream from the gene EPHA7 on chromosome 6, was significantly 
associated with BDRABS (β=0.11, P=8.29×10−9). This variant was also associated with 
BDRPRED (β=3.22, P=1.03×10−7) and BDRBASE (β=7.06, p=5.64×10−6), though the P-
values were not genome-wide significant.
Table 3 presents the top SNPs annotated to genes having P < 5×10−6 for the COPDGene AA 
subjects. The full list of SNPs with P < 5×10−6 are presented in Supplementary Tables 4–6. 
Variants in the gene CDH13 were significantly associated with BDRABS (rs115067260; 
β=0.17±0.03, P=5.05×10−9) and BDRPRED (rs114132812, β=7.63±1.32, P=1.19×10−8), 
and showed suggestive association with BDRBASE (rs77347308 β=−17.14±3.39, 
P=5.35×10−7). In addition, a genotyped SNP in the gene SGCD was significantly associated 
with BDRBASE (rs10056066, β=7.12±1.29, P=4.86×10−8), and several rare imputed SNPs 
in the gene GOLGA8B were associated with the outcome BDRPRED (rs76677753, 
β=9.49±1.67, P=1.9×10−8). A recent GWAS using COPD subjects from the Lung Health 
Study population identified the variants in the gene SGCD as associated with airway 
responsiveness measured by methacholine challenge test in a physiologically distinct asthma 
cohort(24). While the response to inhaled methacholine is distinct from the response to 
inhaled bronchodilators, similar mechanisms of smooth muscle activation could be involved. 
We tested the two top SGCD SNPs from that study in our AA population. The SNP 
rs456290 was associated with BDRBLINE (P=0.02), and the SNP rs2642660 approached 
replication (P=0.08). These SNPs were not associated with BDRBLINE in the NHW 
population, or in the meta-analysis.
The CDH13 SNPs were in LD (rs115067260 and rs114132812, R2=0.60, D’=1.0). These 
variants were monomorphic in the Caucasian populations. We tested additional variants 
within CDH13 in the COPDGene NHW subjects for association with BDR. Rs4783331 was 
nominally associated with BDRABS (β=0.11±0.02, P=9.39×10−5), and five additional SNPs 
in this gene had P<0.001.
We tested our model assumptions of normal distributions of the BDR traits, focusing on 
BDRABS in the African Americans. The BDR traits appeared to fit a normal distribution 
(Supplementary figure 1). We additionally examined the residuals from linear regression for 
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the BDR outcomes in the African American subjects, adjusted for age, pack-years, and 
gender, which appeared normally distributed and were consistent with our model assumption 
(Supplementary figure 2). We performed an inverse normal transformation of the BDRABS 
phenotype, and tested this trait in a GWAS. The CDH13 SNPs, rs115067260 (P=4.46×10−6) 
and rs114132812 (P=5.10×10−6), remained the top associations. Taqman genotyping verified 
the imputation accuracy of the CDH13 SNPs. 22/23 imputed carriers of the SNP 
rs114132812 were heterozygous for the minor allele, and for rs115067260, 35/37 subjects 
were verified as heterozygous and one subject homozygous for the minor allele.
We performed a meta-analysis of the results of all five study populations (Table 4, Figure 1). 
A SNP in the potassium channel, subfamily K, Member 1 gene (KCNK1) demonstrated 
suggestive association with the outcome BDRABS (β =−0.0142, P=2.02×10−7). A SNP 
upstream from the gene KCNJ2 (rs9898686) showed suggestive association with all three 
traits: BDRABS, (β =0.014, P=2.05×10−7), BDRBASE (β=1.26, P=1.83×10−7) and 
BDRPRED (β =0.44, P=1.22×10−6). Variants in the gene MC5R (melanocortin 5 receptor) 
were suggestively associated with BDRPRED (rs12956045, β= −0.45, P=4.69×10−7). 
Several other variants in the KCNJ2 region also demonstrated nominal association, and these 
variants were in linkage disequilibrium (R2>0.80). SNPs upstream from KCNJ2 were 
recently identified as associated with lung function (measured by FEV1) in a joint meta-
analysis of SNP and SNP-by-smoking effects in a population-based sample(25). We 
examined the top SNP from that analysis, rs11654749. This SNP was nominally associated 
with BDRABS in COPDGene NHW subjects, with the same effect direction (β=0.011, 
P=0.007). We performed the meta-analysis without the AA population (Supplementary 
Table1), with very similar results as that including all five study populations together.
We examined SNPs previously associated with BDR in asthma GWAS (9, 11, 26, 27) 
(Supplementary Table 9). In asthma, the SNP rs4452682 in the gene SLC22A23 was 
associated with BDR(11). This SNP was nominally associated with BDRBASE in the 
COPD meta-analysis (β =0.63, P=2.5×10−3), although the effect size was in the opposite 
direction. A rare variant in the gene SLC24A4 was also previously associated with BDR in 
an asthma study(26). Although this SNP, rs77441273, was not present in our GWAS meta-
analysis, several SNPs in this gene demonstrated nominal association with BDRABS 
(rs60243508, β=0.017, P=0.008). The gene SPATA13 was previously associated with BDR 
in a gene-based GWAS among African Americans with asthma(27). Although this gene did 
not replicate in our gene-based VEGAS analysis and the top reported SNP did not replicate 
in our meta-analysis, we tested all 464 of the genotyped and imputed SNPs available in the 
gene SPATA13 for their association with BDRABS. Twenty-eight of these SNPs were 
nominally associated with BDRABS in the COPD meta-analysis, including rs9511156 
(β=0.02, P=0.007); however these associations were not significant after correction for 
multiple testing. In addition, among the COPDGene AA population, the top SNP rs9507294 
from the asthma study showed nominal association with BDRBASE (β=1.94 , P=0.05). The 
remainder of the asthma GWAS SNPs were not significantly associated with BDR in the 
COPD analyses, and none of the asthma BDR genes were significant in the gene-based 
VEGAS analysis. The ADRB2 codon 16 and 27 SNPs (rs1042713 and rs1042714) that have 
been previously identified in asthmatic populations were not significantly associated with 
BDR in the COPD GWAS. None of the top COPD variants were associated with BDR when 
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examined in two prior asthma GWAS(9, 11). The SNPs from candidate genes previously 
associated with BDR in COPD populations (6), including EPHX1 (rs3753661), SERPINE2 
(rs6712954), and ADRB2 (rs1042717), were not associated with BDR in our analysis.
We tested the top SNPs from the BDR meta-analysis for association with lung function in 
four of the five COPD populations (COPDGene NHW and AA, GenKOLs, ECLIPSE). SNP 
rs61824320 in the gene KCNK1 was significantly associated with FEV1/FVC (β= −0.0042 , 
P=0.03) and FEV1 (β= −0.02 , P=0.04) (M. Cho and S. Lutz, personal communication). The 
remainder of top SNPs from the BDR meta-analysis were not significantly associated with 
lung function.
In the VEGAS gene-based analysis (Supplementary Tables 10–12), using the P value results 
from the meta-analysis of all five studies, KCNK1 approached genome-wide significance for 
the outcome BDRABS (P=8.4×10−5) and BDRPRED (P=3.8×10−4). The gene SH2B 
adaptor protein 3, SH2B3, was a top gene for all three traits, approaching genome wide 
significance for BDRABS (P=3.20×10−5), BDRPRED (7.0 × 10−5) and BDRBASE (1.50 × 
10−5). We examined the top genes from the GWAS in the VEGAS analysis. KCNJ2 and 
SGCD were not significant in the gene-based analysis; however, CDH13 showed nominal 
significance for all three traits. We additionally performed Gene Ontology analysis of the top 
50 genes from the GWAS and from the VEGAS analysis using the functional annotation 
software, DAVID. Among the top genes in the GWAS, there was enrichment for ion channel 
and ion transport genes, including KCNK1, FXYD1, and PKD2L1. Among the top genes 
from the VEGAS analysis, there was enrichment for chemotaxis and lipid biosynthesis.
Discussion
This is the first genome-wide association study of the response to inhaled β2-agonists among 
COPD subjects. In a meta-analysis including five COPD populations and over 5000 subjects, 
we identified several genetic variants associated with the response to inhaled β2-agonist 
bronchodilators. In the African-Americans from COPDGene, several variants in the genes 
CDH13 (Cadherin-13), SGCD (Sarcoglycan delta), and GOLGA8B (golgin A8 family, 
member B) demonstrated genome-wide significance for their association with the response 
to β2-agonists. In the non-Hispanic white COPDGene population, SNPs upstream and 
within the potassium channel genes, KCNJ2 and KCNK1 respectively, approached genome-
wide significant association with the response to inhaled bronchodilators. This association 
remained in a meta-analysis including all five COPD case populations, although not at the 
genome-wide significance level.
In the primary analysis among the COPDGene NHW population, the SNP rs17575208 on 
chromosome 6 upstream from the gene Ephrin-type A receptor 7, EPHA7, was genome-
wide significant with a P value of 7.23×10−9 for the outcome BDRABS, 8.3×10−8 for 
BDRPRED and 4.15×10−6 for BDRBASE. Although mutations in this gene have been found 
in resected non-small cell lung cancer human specimens, little is known about a potential 
role for EPHA7 in COPD, asthma, or BDR. In our meta-analysis, this SNP had a P value of 
2.32 × 10−5 for the outcome BDRABS and 1.30×10−4 for the outcome BDRPRED, however 
the association was not significant among the other populations tested (P>0.05). This is an 
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imputed SNP with minor allele frequency of 1.4% but good imputation quality (R2 = 0.82), 
and therefore may suggest a promising gene for future studies.
We identified several SNPs on chromosome 17 upstream from KCNJ2, also known as 
KIR2.1 or Potassium inwardly-rectifying channel, subfamily J, member 2, that were 
suggestively associated with BDR. Inwardly-rectifying potassium channels were initially 
described in cardiac, skeletal, and brain tissue, and especially in smooth muscle of small 
arterioles. These channels play a role in potassium-mediated constriction in response to 
hypoxemia or ischemia(28). KCNJ2 encodes Kir2.1, a strong inwardly rectifying potassium 
channel, which has been identified in small and large bronchial smooth muscle cells and 
plays a role in membrane depolarization (29) (30). Although the exact role for these 
channels in smooth muscle relaxation remains to be determined, it is possible that these 
channels play a role in the response to increased extracellular potassium, such as that 
induced by hypoxemia or acidic environments, leading to membrane hyperpolarization and 
smooth muscle relaxation(28, 30).
Genotyped and imputed SNPs within the potassium channel gene, KCNK1, located on 
chromosome 1, were also associated with BDRABS. This gene is also known as TWIK-1, 
and encodes the 2-pore protein potassium channel subfamily K member 1, or inward 
rectifying potassium channel protein TWIK-1. Two-pore potassium channels have been 
identified in a lung epithelial cell line(31). TWIK-1 transcript has been identified on the 
apical membrane of human bronchial epithelial cells, and has been suggested to play a role 
in hyperpolarization of membrane action potential(32). The top variant in this gene was 
additionally associated with measures of lung function, suggesting a potential link to COPD 
severity. Further studies will be necessary to confirm the roles of these potassium channel 
genes in BDR and COPD severity.
The identification of multiple potassium channel genes in the single SNP and gene-based 
analyses suggests a potential role for these channels in moderating the response to inhaled 
bronchodilators. Further, both the GWAS and gene-based analysis were enriched for ion 
channel genes. Cellular potassium levels play a key role in maintaining membrane potential, 
and potassium channels have been demonstrated to mediate the effects of β-agonists(2). 
Other potassium channel genes, such as the KCNQ voltage activated channels, have been 
found to ameliorate methacholine bronchoconstriction in rat lung models(33), and these 
inwardly-rectifying potassium channels may play a similar role in bronchial smooth muscle 
relaxation. The potassium channel opening medication cromakalin has been tested in animal 
and human asthma subjects(34). However, limited knowledge is available about the role of 
potassium channels in mediating smooth muscle relaxation. The identification of potassium-
channel genes suggests the importance of revisiting this class of medications for COPD and 
asthma therapeutics.
We noted a statistically significant, but clinically small, difference in the response to inhaled 
β2-agonists between the non-Hispanic white and African American subjects in COPDGene. 
To our knowledge, this is the first demonstration that NHW and AA subjects with COPD 
may respond differently to inhaled β2-agonists. Because of this difference, we examined the 
AA population alone for variants associated with BDR. In AA subjects, SNPs in the genes 
Hardin et al. Page 8
Pharmacogenomics J. Author manuscript; available in PMC 2016 August 10.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
CDH13, SGCD, and GOLGA8B were associated with bronchodilator responsiveness. 
CDH13 encodes the protein T-cadherin, which functions as an adiponectin receptor(35) and 
is expressed in mouse lungs in response to allergen stimulation with ovalbumin (36). 
Adiponectin is protective against allergen-induced inflammatory cell response in mouse 
lungs and airway hyperresponsiveness(37) and T-cadherin knock-out mice demonstrate 
reduced immune response, airway hyperresponsiveness, and mucus hyperplasia compared to 
wild-type mice (36). Elevated adiponectin levels have been associated with increased 
radiographic measures of percent emphysema and lower response to inhaled bronchodilators 
among subjects with COPD(38).
SGCD encodes the dystrophin-sarcoglycan complex protein subunit sarcoglycan-δ. This 
protein complex is expressed in skeletal and cardiac muscle and is thought to play a role in 
limb girdle muscular dystrophy(39). The delta-sarcoglycan complex has been identified in 
airway smooth muscle cells, and plays a role in mediating the transition of airway smooth 
muscle cells from contractile to proliferative phenotypes(40), suggesting a possible role in 
COPD pathogenesis. In addition, variants in the SGCD gene were recently associated with 
airway hyperresponsiveness in a GWAS among COPD subjects from the large multicenter 
Lung Health Study. These variants were also nominally associated with BDRBLINE in our 
population.
Variants in the gene GOLGA8B (Golgin A8 Family, Member B, GOLGA8B) were 
associated with BDRPRED and approached significant association with BDRABS. 
Although these were imputed SNPs with low minor allele frequency, the imputation was of 
good quality. GOLGA8B encodes a golgi system autoantigen, and this region has been 
associated with myopia in a large GWAS(41), although a potential role in bronchodilator 
responsiveness is unknown.
We examined the response to an inhaled bronchodilator as a quantitative variable using three 
measures that have been used in prior epidemiologic and genetic studies(5, 6). In a family-
based study, Palmer and colleagues demonstrated that both BDRABS and BDRPRED have 
greater than 30% heritability, while BDRBASE is less heritable(5), suggesting that all three 
outcomes were suitable phenotypes to test for genetic association. The absolute change in 
FEV1 after β2-agonist administration is the most straightforward measure, but it does not 
account for baseline lung function, which is reduced in COPD. In contrast, BDRBASE has 
been shown to correlate with baseline lung function(42). These variables were all highly 
correlated. As no single measure appears to be the most comprehensive, we analyzed all 
three traits.
Quantitative measures of the response to inhaled bronchodilators differ from the binary 
definition used by the American Thoracic Society and European Respiratory Society(1). 
Prior studies have suggested that this binary outcome does not identify a phenotypically 
distinct subset of COPD patients, since the presence or absence of a bronchodilator response 
does not predict clinical outcomes and demonstrates intra-individual variability (42, 43). In 
contrast, linkage and candidate gene studies have previously identified genetic risk factors 
for quantitative measures of bronchodilator responsiveness(5, 6). In addition to our new 
GWAS results, these genetic associations suggest that there are distinct genetic risk factors 
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that play a role in determining the quantitative response to inhaled β2-agonists. Identifying 
these markers may help to identify COPD patients who demonstrate a greater response to 
β2-agonists, or who may be unlikely to benefit and therefore should be prescribed alternative 
medications.
Several GWAS have identified SNPs and genes associated with BDR in asthma (8, 11, 26, 
27, 44). We examined the top variants from the asthma studies for association with BDR in 
the COPD populations, as well as SNPs in the ADRB2 gene that have previously been 
associated with clinical response to long-acting β2-agonist administration in COPD(44–46). 
A variant in the SLC22A23 gene was nominally associated with BDR in COPD, although 
the effect size was in the opposite direction as originally reported. A previously identified 
intergenic SNP, rs11252394, on chromosome 5 also suggested significant association with 
BDRABS. However, none of the other asthma BDR variants demonstrated significant 
association. Although ADRB2 may be a candidate gene for bronchodilator responsiveness in 
asthma, variants from this gene have not demonstrated consistent association with BDR in 
COPD (6, 47, 48).
Our study has several limitations. It is common for investigators to replicate top GWAS 
findings in a replication population. However, in order to improve our power to detect an 
association, we used all available COPD cohorts in our meta-analysis to perform the largest 
GWAS of BDR to date. Our most significant findings are in biologically plausible genes, 
and the effect sizes are similar across all included cohorts. It is encouraging that we did find 
some cross-over between our top hits and those in asthma populations for both 
bronchodilator responsiveness and airway hyperresponsiveness despite the fact that these are 
different study populations. Although we identified several variants upstream from KCNJ2 
as associated with BDRABS and BDRPRED, these results failed to meet genome-wide 
significance in the meta-analysis. An examination of each population demonstrates that 
these variants all had a similar effect size (Supplementary Figure 1, Supplementary Table 8), 
suggesting that the lack of significance may be related to sample size. In contrast, studies 
that have identified variants associated with lung function in the general population have had 
sample sizes up to ten times larger than the current study(49). This is the only genome-wide 
study of the response to inhaled bronchodilators in COPD performed to date. We were 
specifically interested in identifying genes associated with BDR in COPD populations, and 
therefore we are limited to available COPD cohorts for this analysis. Although the GWAS 
meta-analysis did not demonstrate genome-wide significance, the top SNP is upstream from 
the gene KCNJ2, and the protein-product potassium channel is relevant to the phenotype 
being studied. In addition, variants in this same region have previously been associated with 
lung function. We are additionally limited by the use of a one-time measurement of 
bronchodilator responsiveness. Although BDR as a binary trait is not necessarily stable in an 
individual COPD patient over serial measurements (43), we used quantitative outcomes in 
this analysis. Post-bronchodilator FEV1 is a stable phenotype over time(5), diminishing the 
noise in the quantitative measures. However, the presence of intra-individual variability may 
have diluted our ability to identify a significant genome-wide association. Future 
longitudinal studies in these populations that can account for intra-individual variability may 
better identify genetic risk factors for these outcomes.
Hardin et al. Page 10
Pharmacogenomics J. Author manuscript; available in PMC 2016 August 10.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Within the COPDGene African American subjects, there were several SNPs that 
demonstrated genome-wide significance, but were of low minor allele frequency, including 
imputed SNPs in CDH13. However, all SNPs had a minor allele frequency greater than 1%, 
with excellent imputation quality (R2 ≥ 90%). Although the BDR outcomes were normally 
distributed, minimal skewing could result in false positive associations especially among 
variants with low minor allele frequency. In order to test our assumption of normality, we 
performed inverse normal transformation of the BDR outcomes and tested for variants for 
association with this transformed outcome. The order of SNPs was preserved with this 
transformed outcome, suggesting that our assumption of normality was correct. We 
confirmed imputation accuracy through direct genotyping. Furthermore, animal studies 
provide good evidence that CDH13 is biologically plausible as a gene potentially involved in 
the bronchodilator pathway. Although the top variants associated with BDR in the AA 
population were monomorphic in the Caucasian populations, several other CDH13 variants 
were nominally associated with BDR. In addition, the gene-based test identified this gene as 
nominally associated with bronchodilator responsiveness even though the top SNPs in the 
AA analysis were not included in the gene-based test.
In summary, in the largest COPD pharmacogenetics GWAS to date, we demonstrated that 
variants upstream from the gene KCNJ2 are associated with response to an inhaled short 
acting β2 -agonist bronchodilator. In addition, several SNPs in the genes CDH13 and SGCD 
were significantly associated with BDR in African Americans. These results may point to 
novel assessments or potential novel therapeutic pathways for COPD. Future studies will 
require larger COPD populations to identify genome-wide significant variants, and 
functional studies will help to identify a role for the SNPs and genes highlighted in the 
GWAS.
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Figure 1. 
Manhattan plots for meta-analysis results for each bronchodilator responsiveness outcome
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Figure 2. 
Regional association plot for KCNJ2 variants associated with the outcome BDRABS
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